Viva Biotech Highlights AI and Flow Chemistry Integration for Scalable Drug Synthesis
Viva Biotech hosted a webinar titled "AI x Flow Chemistry: From Bench to Business" to explore how artificial intelligence and flow chemistry are shaping modern synthesis workflows, announced in a press release. The event featured academic and industry experts discussing how these technologies are bridging the gap between molecular design and scalable execution.
Professor Jie Wu from the National University of Singapore presented advances in automated multistep synthesis, emphasizing the use of high speed circulation flow systems that combine batch and continuous processing. He introduced Chemical Recipe Files as a method to encode optimized synthesis protocols in a reproducible, machine executable format, supporting automated and scalable workflows.
Dr. Kejia Ding from Viva Biotech described how flow chemistry is being deployed across medicinal chemistry, process development, and manufacturing. Case studies included photochemical and difluoromethyl syntheses, where flow processing improved safety and scalability. A subsidiary, Langhua Pharma, demonstrated a continuous flow Curtius rearrangement that produced one thousand kilograms of material within two months.
The discussion highlighted how combining AI with automated synthesis and flow chemistry enables faster experimental validation of digitally designed molecules. Viva Biotech’s integrated platform connects discovery, synthesis, and manufacturing capabilities to support partners from early research through production.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 13 Bracco and Avicenna.AI win FDA clearance for AI that flags brain aneurysms on CT scans Nov 13 Zus Health raises $33 million to build the data layer for healthcare AI Nov 13 Google DeepMind releases AlphaGenome 2 to predict DNA variant effects in specific cell types Nov 13 Taiwan hospital accelerator T+ MedIC names AI ECG and CT screening tools as first winners Nov 13 Sheinbaum meets OpenAI president Greg Brockman on AI in Mexican healthcareLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Atlas Bio raises $12.5 million for virtual drug trials
Crediflow AI raises €1.8 million for loan processing software
PharmaForceIQ Launches Share of Answer for Pharma AI Visibility
Benchling Launches Science Foundries for Biotech R&D
BioMap Announces 11 AI Life Science Collaborations
Daily AI Brief: the AI news that matters, in your inbox.